Zynex (NASDAQ:ZYXI) Releases Earnings Results, Beats Estimates By $0.01 EPS

Zynex (NASDAQ:ZYXI) issued its quarterly earnings results on Thursday. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01, Briefing.com reports. Zynex had a return on equity of 14.15% and a net margin of 3.12%. The firm had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. During the same quarter last year, the business posted $0.10 EPS. Zynex’s revenue was up .1% on a year-over-year basis.

Zynex Price Performance

ZYXI opened at $9.12 on Friday. The stock has a fifty day moving average price of $8.01 and a 200 day moving average price of $9.20. The company has a current ratio of 4.06, a quick ratio of 3.22 and a debt-to-equity ratio of 1.79. Zynex has a 1 year low of $7.04 and a 1 year high of $13.77. The stock has a market cap of $289.79 million, a price-to-earnings ratio of 39.65 and a beta of 0.54.

Insiders Place Their Bets

In other news, COO Anna Lucsok sold 8,083 shares of Zynex stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares in the company, valued at $136,349.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Anna Lucsok sold 8,083 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total transaction of $64,906.49. Following the transaction, the chief operating officer now owns 16,980 shares in the company, valued at approximately $136,349.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joshua R. Disbrow acquired 7,000 shares of Zynex stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, with a total value of $58,240.00. Following the purchase, the director now owns 72,000 shares in the company, valued at $599,040. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 52.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ZYXI shares. Royal Bank of Canada cut their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright boosted their target price on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Friday.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.